Clinical Trial Update: Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for Endothelial Monocyte-activating Polypeptide-II in Egyptian patients with Sickle Cell Disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Endothelial Monocyte-activating Polypeptide-II (Endothelial Monocyte-activating Polypeptide-II)

Snippet

Sponsor: Ain Shams University | Conditions: Sickle Cell Disease | Phase 4 | Status: COMPLETED